Back to search

Article

A novel decision-making tool for first-line treatment selection in metastatic non-small cell lung cancer based on plasma proteome profiling

2022-12-03

Abstract excerpt

<h4>Importance</h4> Advanced stage non-small cell lung cancer (NSCLC) patients with no driver mutations are typically treated with immune checkpoint inhibitor (ICI)-based therapy, either in the form of monotherapy or concurrently with chemotherapy, while treatment modality selection is based mainly on programmed death ligand 1 (PD-L1) expression levels in the tumor. However, PD-L1 assays are only moderately predic...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
59bde87a-a774-5930-b556-ea567bc92af3
DOI
10.1101/2022.12.01.22282769
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A novel decision-making tool for first-line treatment selection in metastatic non-small cell lung cancer based on plasma proteome profilingDOI 10.1101/2022.12.01.22282769
Plasma proteome-based test (PROphetNSCLC) predicts response to immune checkpoint inhibitors (ICI) independent of tumor programmed death-ligand 1(PD-L1) expression and tumor mutational burden (TMB)Semantic proximity
Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: a comprehensive analysis of plasma proteomics and therapeutic implicationsSemantic proximity
Multimodal profiling for prediction of primary resistance to anti–PD-(L)1 therapy in advanced non-small-cell lung cancer: the prospective PIONeeR biomarkers studySemantic proximity
Integrating clinico-pathological features and longitudinal liquid biopsy results to predict clinical benefit from immune checkpoint Inhibitors in advanced Non-Small Cell Lung Cancer patientsSemantic proximity
Predictive value of the biomarker of peripheral blood of NSCLC patients responding to anti-PD-1 treatmentSemantic proximity
PD-L1 status on Circulating Tumor Cells: A Promising Predictor in Advanced Lung Cancer with PD-1/PD-L1 immunotherapiesSemantic proximity
Prediction of 2-Year Mortality in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors Based on a Machine Learning AlgorithmSemantic proximity
Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapySemantic proximity
Blood immunomap for prediction of responses to aPD1 immunotherapy in metastatic non-small cell lung cancerSemantic proximity
Bioinformatics analysis of NSCLC multi-omics dataSemantic proximity
Efficacy and safety of different PD-1 inhibitors as first-line treatment for advanced or metastatic squamous non-small cell lung cancer: A retrospective real-world studySemantic proximity
Blood immunomap for prediction of responses to aPD1 immunotherapy in metastatic non-small cell lung cancerSemantic proximity
Select a neighboring publication to make it the new centre.